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Objective. We assessed adolescent anthropometry, lipids, insulin, glucose, and blood pressures to identify factors associated
with high-sensitivity C-reactive protein (hsCRP) and its tracking in young adults. Methods. Ten-year prospective study of 589
schoolgirls, 321 black, 268 white. Results. HsCRP did not diﬀer (P>. 08) by race or oral contraceptive use. HsCRP tracked from
a g e1 6t o2 5( r = 0.7 7 ) ,1 6t o2 6( r = 0.5 0 ) ,2 4t o2 6( r = 0.66), and 25 to 26 (r = 0.71), all P ≤ .02. By stepwise regression,
at age 16, waist circumference accounted for 44.8% of hsCRP variance; BMI accounted for 33.1%, 34.4%, and 31.1% at ages 24,
25, and 26, P<. 0001 for all. Changes in cholesterol and BMI were associated with change in hsCRP from age 24–26 (partial
R2 = 12.3% P<. 0001, 6.6% P = .0012). Changes in BMI and triglyceride (partial R2 = 8.5% P = .0001, 3.3%, P = .0045) were
associated with change in hsCRP from age 25 to 26. Conclusions. HsCRP tracks from age 16 to 26, with BMI, waist circumference,
and cholesterol as major determinants.
1.Introduction
The anatomic and pathophysiological genesis of atheroscle-
rosis is in childhood [1–5]. The traditional Framingham risk
factors (hyperlipidemias, blood pressure, obesity, diabetes,
and cigarette smoking) have been used as the starting point
for evaluating individual risk to vascular disease, and each
factor is strongly associated with increased risk to coronary
heart disease (CHD) in adults and, in children, associated
with family history of CHD [6–9]. It has been estimated
that the traditional CHD risk factors may explain about
50% of CHD morbidity and mortality [9], eliciting eﬀorts to
identify additional predictive factors, such as high-sensitivity
Cr e a c t i v ep r o t e i n( h s C R P )[ 10].
Biomarkerspredictiveofinﬂammatory processesinacute
clinical settings (e.g., during infection or after traumas)
have become valuable predictors of future vascular events
[11]. This primal organism response to invading pathogens,
trauma, or chronic inﬂammation presumably represents a
protective mechanism and involves a cascade of thrombotic
and inﬂammatory factors of variable expression [11]. In the
chronic state, acute phase reactants have become important
predictors of future vascular events: thus, baseline serum
high-sensitivity c-reactive protein (hsCRP) values have been
correlated with the development of CHD in healthy men
[11, 12]a n dw o m e n[ 11] in the Harvard Study population,
corroborated by other groups [13, 14]. In a prospective
study of 506 men who had fatal CHD or had a nonfatal2 ISRN Pediatrics
myocardial infarction compared to 1025 men free of CHD,
men in the top third for entry hsCRP had an odds ratio
for CHD of 2.13 (95% conﬁdence interval 1.38–3.28) after
age, town, smoking, vascular risk factors, and indicators of
socioeconmic status were adjusted for [15]. The cascade of
TNF-α and IL-6 elevation leads to increments in hsCRP
andﬁbrinogen, with resultingadhesion moleculeexpression,
and may facilitate development of type 2 diabetes mellitus
(T2DM) as well as CHD [16].
Cross-sectional studies in children have shown a strong
association between hsCRP and obesity, triglycerides, HDL
cholesterol, diastolic blood pressure, and ﬁbrinogen [17–
20]. Longitudinal data from the Young Finns Study [21]
showed that hsCRP tracked signiﬁcantly from ages 3–18
years (at entry) to ages 24–39 years. Tracking was greater in
the older children and in women than men [21]. By multi-
variate analysis, adult carotid artery intimal medial thickness
(cIMT)wasassociatedwithchildhoodelevatedsystolicblood
pressure, high LDL cholesterol, and smoking, but not with
childhood hsCRP [21]. J¨ arvisalo et al. [22], however, showed
that elevated hsCRP levels in children are associated with
increased cIMT as well as with decreased brachial artery
ﬂow-mediated dilatation, and Zieske et al. [23]r e p o r t e d
thatserumhsCRP isindependentlyassociatedwith advanced
atherosclerosis in youth. Thus, in aggregate, these studies
suggest that measurement of hsCRP in childhood [21–23]
might predict adult cardiovascular risk.
The National Growth and Health Study (NGHS) [24],
its ancillary studies, and the extension of the followup of
theCincinnati cliniccohortby investigator-initiated research
projects, provide an opportunity to assess hsCRP tracking
in black and white females from mid-adolescence to young
adulthood and to identify factors associated with high
concentrations of hsCRP and with its tracking.
2.Materialsand Methods
2.1. The Study Population. The NGHS has been described
previously [24]. Brieﬂy, NGHS was a 10-year (1987–1997)
multicenter cohort study to explicate origins of black-white
disparities in obesity and its eﬀects on cardiovascular (CVD)
risk factors in women [24]. Race was self-declared and
enrollment was restricted to 9- and 10-year old girls from
racially concordant households, that is, to girls who said
they were black or white and whose parents or guardians
said that they were black or white, respectively. In ancillary
projects, the Cincinnati clinic measured fasting insulin at
Visit 7 (mean ± SD age 16 ± 1), in addition to the NGHS
variables—lipid proﬁles, apo A1, systolic and diastolic blood
pressure [25]. At age 16, hsCRP was measured in a subset of
participants as a pilot project. After completion of NGHS,
the Cincinnati clinic extended followup with measurement
of insulin to age 25 and collected hsCRP at ages 24, 25, and
26.
IntheNGHS[25],anditsextension,proceduresfollowed
were in accordance with the ethical standards of the Institu-
tionalReviewBoardsoftheCenters,whoapprovedthestudy.
Signedinformedconsentwasobtainedfromthegirls’parents
or guardians and assent from the girls.
2.2. Laboratory and Clinical Measurements. Methods for
measurementoflipids,fastingseruminsulin,glucose,height,
weight, waist circumference, and systolic and diastolic blood
pressure have been previously described [24, 25]. Fasting
glucose was measured at ages 10 and 19–24, insulin at ages
10, 16, and 19–25.
At each visit, girls were asked whether they were taking a
birth control pill, since hsCRP may be elevated by estrogen-
progestin oral contraceptives [26].
The NGHS used BMI to assess overweight annually
according to a standard protocol [24], as recommended by
several expert panels [27–29] and waist circumference as an
indicator of fat patterning.
Using criteria previously described [30], NGHS subjects
having fasting blood glucose >126mg/dl [31]a ta g e1 0
or type 1 DM at any time from age 10 through age 25
were excluded (n = 7) from the analysis sample for this
report. Diagnosis of diabetes was based on WHO criteria,
fasting glucose ≥126mg/dl, and self-reported diabetes with
treatment by a physician [31]. We did not have measurement
of C-peptides as well as diabetes autoantibody levels, gold
standard methods [32] to distinguish type 1 from type 2
diabetes.
Fasting serum insulin levels (competitive protein-
binding radioimmunoassay) were measured after an
overnight fast (≥8hr) using the Michigan Diabetes Research
and Training Center (Ann Arbor) at age, and using the
Endocrine Lab at the University of Cincinnati/Children’s
Medical Center at ages 16,19, and 20 to 25.
HsCRP was measured using the N high-sensitivity latex-
enhanced immunonephelometric (BN 100 nephelometer,
Dade Behring) assay.
2.3. Statistical Methods. Since hsCRP was not normally
distributed,black-whitediﬀerencesinhsCRPanddiﬀerences
between birth control pill users and nonusers were assessed
by Wilcoxon rank sum tests. For assessment of changes in
hsCRP and for regression analyses, hsCRP was transformed
in logarithm scale.
Spearman correlations were used to assess the tracking
of hsCRP from age 16 to 26 years, Table 1.A f t e ra d j u s t i n g
for age, race, BMI, waist circumference, insulin, maximum
glucose, total cholesterol, HDL cholesterol, LDL choles-
terol, triglyceride, and systolic and diastolic blood pressure,
Spearman partial correlations were also calculated to assess
the tracking of hsCRP from ages 24 to 26, and 25 to 26,
Table 1.
Spearman correlations were used to assess the associ-
ations of hsCRP with cardiovascular risk factors at ages
16, 24, 25, and 26 years including age, race, BMI, waist
circumference, insulin, total cholesterol, triglyceride, HDL
cholesterol, LDL cholesterol, systolic blood pressure, dias-
tolic blood pressure, and maximum glucose, Table 2.T h e
Hochberg-Benjamini [33] False Discovery Rate (FDR) for
multiple comparisons was used, Table 2.
After log transformation of hsCRP, all of the variables
from Table 2 were incorporated as candidate explanatory
variables into stepwise regression models with hsCRP as the
dependent variable at ages 16, 24, 25, and 26, Table 3.ISRN Pediatrics 3
Table 1: Simple and partial correlations of hsCRP from age 16 to
age 26 years.
At age 16 At age 24 At age 25 At age 26
hsCRP ﬁrst measured n = 37 n = 166 n = 366 n = 20
Spearman correlation
with hsCRP measured
at age 16
n = 37 n = 6
n = 22
r = 0.77
P<. 0001
n = 21
r = 0.50
P = .021
Spearman correlation
with hsCRP measured
at age 24
n = 172 n = 3
n = 147
r = 0.66
P<. 0001
partial∗
n = 139
r = 0.63
P<. 0001
Spearman correlation
with hsCRP measured
at age 25
n = 391
n = 225
r = 0.71
P<. 0001
partial∗
n = 223
r = 0.54
P<. 0001
hsCRP measured at
age 26 n = 392
∗partialed by age, race, BMI, total, HDL, and LDL cholesterol, triglyceride,
insulin, systolic blood pressure and diastolic blood pressure, all at the same
age, and by maximum glucose measure from age 10 to age 24 years.
Spearman correlations were used to assess relationships
of change in hsCRP (in logarithm scale) from ages 24
to 26 and from 25 to 26 with changes in cardiovascular
disease variables: age, BMI, total cholesterol, triglyceride,
HDL cholesterol, LDL cholesterol, systolic blood pressure,
and diastolic blood pressure during the same period, Table 4.
The FDR approach [33] for multiple comparisons was again
used, Table 4.
All of the variables from Table 4 were incorporated
as candidate explanatory variables into stepwise regression
models with change in hsCRP (in logarithm scale) from age
24 to 26 and from 25 to 26 as dependent variables, Table 5.
3.Results
HsCRP did not diﬀer between birth control pill users versus
nonusers, P ≥ .28 and did not diﬀer by race, P ≥ .09.
Hence, data are presented for the total cohort without
subcategorization by birth control pill use or race.
There were no diﬀerences (P>. 05) in hsCRP or
CVD risk factors between girls with ≥2s e q u e n t i a lh s C R P
measurements and those with only 1 measurement.
Median and interquartile range for hsCRP at age 16 were
1.5(0.7–5.6),atage24,2.0(0.7–4.0),at25,1.7(0.6–4.2),and
at 26, 1.7 (0.6–4.6)mg/L.
3.1. Tracking of hsCRP from Age 16 to Age 26 Years. HsCRP
was measured in 589 girls, 321 black, and 268 white. Subsets
of the cohort had hsCRP measured at diﬀerent ages, 1, 2,
9, and 10 years apart, making possible studies of hsCRP
tracking and factors associated with it, Table 1.T h u s ,t h e r e
were 37 girls having hsCRP measured at age 16 (18 black,
19 white) with subsequent measurements at age 24 (n =
6), 25 (n = 22) and 26 (n = 21), Table 1. In addition,
172 girls (91 black, 81 white) had hsCRP measured at age
24, with subsequent measures at age 25 (n = 3) and
at age 26 (n = 147), Table 1.A d d i t i o n a l l y ,h s C R Pw a s
measured at age 25 in 391 girls (217 black, 174 white) and
subsequently at age 26 in 225 of these girls, Table 1.H s C R P
was measured at age 26 in 392 girls (215 black, 177 white),
Table 1.
Age 16 hsCRP correlated with subsequent measures at
ages 25 (r = 0.77,P<. 0001) and 26 (r = 0.50,P = .02),
Table 1. Age 24 hsCRP correlated with levels at age 26 (r =
0.66,P<. 0001) and age 25 hsCRP correlated with levels at
age 26 (r = 0.71,P<. 0001), Table 1.
After adjusting for age, race, BMI, insulin, maximum
glucose, total cholesterol, triglyceride, HDL cholesterol, LDL
cholesterol, and systolic and diastolic blood pressure, hsCRP
at age 24 remained highly correlated with levels at age 26
(partial r = 0.63,P<. 0001), as did hsCRP at age 25 with
levels at age 26 (partial r = 0.54,P<. 0001), Table 1.
Of 43 girls with hsCRP at age 24 in the top 30% of the
distribution, 24 (56%) remained in the top 30% at age 26,
while26of41(63%)withhsCRPatage24inthebottom30%
of the distributionremained inthe bottom30% at age 26. Of
62 girls in the hsCRP top 30% at age 25, 42 (68%) remained
in the top 30% at age 26, while 49 of 72 (68%) originally in
the bottom 30% at age 25 remained there at age 26.
3.2. Correlates of hsCRP. Of the 37 girls at age 16, signiﬁcant
positive bivariate correlates with hsCRP included BMI, waist
circumference, insulin, and maximum glucose, Table 2.
At ages 24, 25, and 26, signiﬁcant bivariate correlates
withhsCRPincludedBMI,waist circumference,insulin,total
cholesterol, triglyceride, HDL cholesterol, LDL cholesterol,
systolic blood pressure, diastolic blood pressure, and maxi-
mum glucose, Table 2. Age was signiﬁcantly correlated with
hsCRP at age 26.
By stepwise regression, waist circumference (age 16,
partial R2 = 44.8%) and BMI (ages 24, 25, and 26, partial
R2 = 33.1%, 34.4%, 31.1%) were the major signiﬁcant (P<
.0001) explanatory variables for hsCRP, Table 3.A ta g e s2 4
and 25, total cholesterol levels were signiﬁcant explanatory
variables, accounting for 2.5% and 1.9% of hsCRP variance,
Table 3. At age 26, triglyceride accounted for 3.5% of hsCRP
variance, Table 3. With the exception of inclusion of race
as a signiﬁcant explanatory variable at age 26, the results in
Table 3 were identical to results if only those variables which
hadsigniﬁcantbivariatecorrelationsinTable2wereincluded
as candidate explanatory variables (data not shown).
Race was unrelated to change in hsCRP from age
24 to 26, and from age 25 to 26, Table 4.C h a n g e si n
BMI, waist circumference, total cholesterol, triglyceride, and
LDL cholesterol were positively and signiﬁcantly related to
changes in hsCRP from ages 24 to 26, Table 4.C h a n g e si n
BMI, waist circumference, total cholesterol, and triglyceride
were positively and signiﬁcantly related to changes in hsCRP
from age 25 to 26, Table 4.4 ISRN Pediatrics
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Table 3: Stepwise regression of hsCRP at ages 16, 24, 25, and 26 hsCRP are log transformed. Explanatory variables include race, age,
BMI, waist circumference, insulin, TC, TG, HDLC, LDLC, systolic, and diastolic blood pressures all at the age when hsCRP measured, and
maximum glucose (from age 10 to age 24). Signiﬁcantlevels: SLE = 0.15, SLS = .05 in stepwise selection.
Dependent variable Signiﬁcantexplanatory variable sign Partial R2 P
hsCRP at age 16 (35 observations used) waist circumference + 44.8% <.0001
hsCRP at age 24 (164 observations used) BMI + 33.1% <.0001
TC + 2.5% .014
hsCRP at age 25 (383 observations used)
BMI + 34.4% <.0001
TC + 1.9% .0008
waist circumference + 0.8% .030
hsCRP at age 26 (386 observations used)
BMI + 31.1% <.0001
TG + 3.5% .0002
Age − 2.1% .0010
Race (W = 1, B = 2) − 1.1% .0092
TC: total cholesterol, TG: triglyceride, HDLC: HDL cholesterol, LDLC: LDL cholesterol.
After including all of the candidate explanatory variables
of Table 4 into a stepwise regression model, change in total
cholesterol and change in BMI were signiﬁcant explanatory
variables for change in hsCRP from age 24 to 26 (partial
R2 = 12.3 % ,6 . 6 % ) ,T a b l e5. Changes in BMI (partial R2 =
8.5%)and change in TG (partial R2 = 3.3%)were signiﬁcant
explanatory variables for change in hsCRP from age 25 to 26,
Table 5.T h er e s u l t si nT a b l e5 w e r ei d e n t i c a lt or e s u l t si fo n l y
those variables which had signiﬁcant bivariate correlations
in Table 4 were included as explanatory variables (data not
shown).
4.Discussion
The chronic expression of acute phase proteins, in the stable,
ostensibly nonacute setting, is of unclear etiology. Such
proteins could be present in excess due to (a) incomplete
resolution of a previous acute episode, (b) ongoing mono-
cyte/macrophage activation, and/or (c) enhanced baseline
production determined by coordinate genetic control. Acti-
vation of the monocyte/macrophage in the acute setting may
be among the ﬁrst dominoes in the inevitable cascade of
e x p r e s s e dc y t o k i n e sa n dg r o w t hf a c t o r s[ 34, 35]. Activated
monocytes produce TNF and IL-1-like cytokines, which lead
to the full acute phase reaction, including hsCRP (17).
In adults, statins lower hsCRP concurrently with LDL
cholesterol, and hsCRP levels achieved on statin therapy
are predictive of CVD event rates irrespective of the lipid
endpoint used [10]. To test the hypothesis whether or not
subjects with normal LDL cholesterol but elevated hsCRP
represent a population at increased risk that might beneﬁt
from statin treatment, the JUPITER trial [10]r a n d o m i z e d
17,802 apparently healthy persons with elevated hsCRP
to 20mg Rosuvastatin daily or placebo. The rates of the
primary endpoint (composite of nonfatal myocardial infarc-
tion, nonfatal stroke, hospitalization for unstable angina,
revascularization, and conﬁrmed death from cardiovascular
causes) were 0.77 and 1.36 per 100 person-years of fol-
lowup in the Rosuvastatin and placebo groups, respectively.
Relative risk reduction was 44% [10]. It was postulated
that hsCRP more accurately selected high-risk subjects than
LDL cholesterol due to hsCRP’s association with multiple
CVD risk factors, thus representing an aggregate-integrated
marker of the total inﬂammatory burden of an individ-
ual [10]. While inﬂammation is a crucial component of
atherothrombosis [36]and patientswithelevatedhsCRPand
low or intermediate LDL cholesterol levels [10, 37]a r ea t
increased vascular risk, it is not known whether inhibition
of inﬂammation per se will lower vascular event rates [36].
A direct test ofthe inﬂammatory hypothesis ofatherothrom-
bosis requires an agent that inhibits inﬂammation without
aﬀecting other components of the atherothrombotic pro-
cess, particularly LDL cholesterol [36]. The forthcoming
cardiovascular inﬂammation reduction trial (CIRT) will
randomize 7000 stable coronary artery disease patients with
persistent elevations of hsCRP to placebo or very low-dose
methotrexate (10mg weekly), a proven anti-inﬂammatory
regimen that reduces TNF-alpha, IL-6, and CRP levels and
is in wide use among rheumatoid arthritis patients [36].
The CIRT trial [36], if successful, would help conﬁrm the
inﬂammatory hypothesis of atherothrombosis and open
innovative, anti-inﬂammatory approaches to the treatment
and prevention of cardiovascular disorders.
It is not yet known whether hsCRP is a risk factor
for cardiovascular disease independent of other known risk
factors [10, 37], nor is it well understood how long hsCRP
would need to be normalized independent of changes in
otherCVDriskfactorstoreduceCVDevents[36].Moreover,
it is not yet known whether hsCRP, a $43 test, is useful in
assessing childhood antecedents of young adult cardiovas-
cular risk above and beyond conventional childhood CVD
risk factors [21], and whether high hsCRP is reversible with
childhood therapeutic interventions. Although Karakas and
Koenig reported that birth control pill use elevated hsCRP
[38], it had no signiﬁcant eﬀect on hsCRP in our current
study.Juonalaetal.[21]reported signiﬁcant21-yeartracking
of hsCRP from childhood and adolescence into the fourth
decade, but hsCRP was not independently associated with
young adulthood carotid intimal-medial thickness (cIMT).
J¨ arvisalo et al. [22], however, showed that elevated hsCRP6 ISRN Pediatrics
T
a
b
l
e
4
:
S
p
e
a
r
m
a
n
c
o
r
r
e
l
a
t
i
o
n
s
b
e
t
w
e
e
n
c
h
a
n
g
e
s
i
n
h
s
C
R
P
(
l
o
g
t
r
a
n
s
f
o
r
m
e
d
)
a
n
d
c
h
a
n
g
e
s
i
n
c
a
r
d
i
o
v
a
s
c
u
l
a
r
d
i
s
e
a
s
e
r
i
s
k
v
a
r
i
a
b
l
e
s
f
r
o
m
a
g
e
s
2
4
t
o
2
6
a
n
d
f
r
o
m
a
g
e
s
2
5
t
o
2
6
.
C
h
a
n
g
e
i
n
A
g
e
R
a
c
e
(
W
=
1
,
B
=
2
)
C
h
a
n
g
e
i
n
B
M
I
C
h
a
n
g
e
i
n
W
a
i
s
t
C
h
a
n
g
e
i
n
T
C
C
h
a
n
g
e
i
n
T
G
C
h
a
n
g
e
i
n
H
D
L
C
C
h
a
n
g
e
i
n
L
D
L
C
C
h
a
n
g
e
i
n
S
B
P
C
h
a
n
g
e
i
n
D
B
P
C
h
a
n
g
e
i
n
h
s
C
R
P
f
r
o
m
a
g
e
2
4
t
o
2
6
n
=
1
4
7
r
=
−
0
.
0
5
1
P
=
.
5
4
n
=
1
4
7
r
=
−
0
.
0
5
3
P
=
.
5
3
n
=
1
4
7
r
=
0
.
2
7
#
P
=
.
0
0
0
8
n
=
1
4
0
r
=
0
.
2
0
∗
P
=
.
0
2
0
n
=
1
4
7
r
=
0
.
2
7
#
P
=
.
0
0
1
0
n
=
1
4
7
r
=
0
.
2
1
∗
P
=
.
0
1
4
n
=
1
4
7
r
=
0
.
4
3
P
=
.
6
1
n
=
1
4
7
r
=
0
.
2
3
#
P
=
.
0
0
4
9
n
=
1
4
0
r
=
0
.
0
9
0
P
=
.
2
9
n
=
1
4
0
r
=
0
.
1
2
P
=
.
1
7
C
h
a
n
g
e
i
n
h
s
C
R
P
f
r
o
m
a
g
e
2
5
t
o
2
6
n
=
2
2
5
r
=
0
.
2
6
P
=
.
7
0
n
=
2
2
5
r
=
−
0
.
0
8
9
P
=
.
1
8
n
=
2
2
5
r
=
0
.
3
6
§
P
<
.
0
0
0
1
n
=
2
2
5
r
=
0
.
3
3
§
P
<
.
0
0
0
1
n
=
2
2
4
r
=
0
.
1
6
∗
P
=
.
0
1
7
n
=
2
2
4
r
=
0
.
2
8
§
P
<
.
0
0
0
1
n
=
2
2
4
r
=
−
0
.
0
6
9
P
=
.
3
0
n
=
2
2
4
r
=
0
.
0
7
9
P
=
.
2
4
n
=
2
2
4
r
=
0
.
0
6
3
P
=
.
3
4
n
=
2
2
4
r
=
−
0
.
1
0
P
=
.
1
4
∗
P
<
.
0
5
,
#
P
<
.
0
1
,
†
P
<
.
0
0
1
,
§
P
≤
0
0
0
1
W
a
i
s
t
:
w
a
i
s
t
c
i
r
c
u
m
f
e
r
e
n
c
e
,
T
C
:
t
o
t
a
l
c
h
o
l
e
s
t
e
r
o
l
,
T
G
:
t
r
i
g
l
y
c
e
r
i
d
e
,
H
D
L
C
:
H
D
L
c
h
o
l
e
s
t
e
r
o
l
,
L
D
L
C
:
L
D
L
c
h
o
l
e
s
t
e
r
o
l
,
S
B
P
:
s
y
s
t
o
l
i
c
b
l
o
o
d
p
r
e
s
s
u
r
e
,
D
B
P
:
d
i
a
s
t
o
l
i
c
b
l
o
o
d
p
r
e
s
s
u
r
e
.ISRN Pediatrics 7
Table 5: Change in hsCRP (logarithm transformed) from age 24 to age 26 and from age 25 to 26.
Dependent variable Signiﬁcantexplanatory variable sign Partial R2 P
Change in hsCRP from age 24 to age 26 (139 observations used) Change in TC + 12.3% <.0001
Change in BMI + 6.6% .0012
Change in hsCRP from age 25 to age 26 (223 observations used) Change in BMI + 8.5% .0001
Change in TG + 3.3% .0045
Dependent variable: hsCRP (logarithm transformed) change.
Explanatory variablesinclude:race,change inage, change inBMI, changes inwaistcircumference,changes inTC, TG,HDLC,and LDLC, andchange inblood
pressure during the same period.
Signiﬁcant levels: SLE = .15, SLS = .05.
levels in children were associated with increased cIMT and
decreased brachial artery ﬂow-mediated dilatation, a marker
ofthelossofvascularﬂexibility.In addition,Zieskeetal.[23]
reported that serum hsCRP is independently associated with
advanced atherosclerosis in youth.
In the current study, there was signiﬁcant tracking of
hsCRP across several years from age 24 to 26 (r = 0.66,P<
.0001) and from age 25 to 26 (r = 0.71,P<. 0001). Similarly
strong long-term correlations were found from age 16to ages
25 (r = 0.77,P<. 0001) and 26 (r = 0.50,P = .02). These
tracking coeﬃcients remained signiﬁcant after adjusting for
multiple CVD risk factors; hsCRP at age 24 remained highly
correlated with levels at age 26 (partial r = 0.63,P<. 0001),
as did hsCRP at age 25 with levels at age 26 (partial r =
0.54,P<. 0001). Exemplifying this strong tracking of hsCRP,
24 of 43 girls (56%) with top 30% hsCRP at age 24 remained
in the top 30% at age 26, while 26 of 41 girls (63%) with
bottom30%hsCRPatage24 remained inthebottom30% at
age26.Of62girlsinthetop30%ofthehsCRPdistributionat
age 25, 42 (68%)remained in the top30% at age 26, while 49
of72 (68%) originally in the bottom30% at age 25 remained
there at age 26.
With exception of the report by Juonala et al. [21],
tracking of hsCRP during childhood and into young adult-
hood has not yet been reported. With 21-year followup from
childhood to young adulthood, Juonala et al. [21]r e p o r t e d
signiﬁcant tracking between childhood and adult hsCRP
levels, highest in 18 years olds at study entry, r = 0.47 in
females, 0.32 in males, and P<. 0001 for both. For the
total cohort, the 21-year tracking correlation for hsCRP was
0.29 [21]. Congruent with the ﬁndings of the current study,
the association between childhood and adult hsCRP levels in
Finns [21] was independent of serum lipids, blood pressure,
smoking, obesity indices, and insulin.
SigniﬁcanttrackingofhsCRPfromchildhoodintoyoung
adulthood speculatively raises the issue whether childhood
hsCRP canpredict adult atherosclerosis orCVD eventsinde-
pendent of traditional cardiovascular risk factors (HDL and
LDLcholesterol,triglyceride,bloodpressure,andobesity).In
the study by Juonala et al. [21], however, childhood hsCRP
was not independently associated with young adulthood
carotid IMT. In 8091, subjects with hsCRP ≥ 2mg/L
randomized to placebo in the JUPITER (Rosuvastatin) trial,
over a 4-year period, the intraclass correlation for repeated
hsCRP measurements was 0.54 (95% CI 0.53–0.55) without
adjustmentand0.50(95%CI0.49–0.51)afteradjustmentfor
demographic, lifestyle, and comorbidity determinants [39],
Glynn etal. [39] concludedthat“...concentrations ofhsCRP
show strong tracking, even after selection of individuals
with initially high values. Without statin therapy, increased
concentrations of hsCRP generally remain high over time.”
Congruent with the ﬁndings of Soriano-Guill´ en et al.
[20], in the current study, at age 16, hsCRP was signiﬁcantly
positively correlated with BMI, waist circumference, and
insulin. Bystepwise regression, waist circumference and BMI
were the major signiﬁcant (P<. 0001) explanatory variables
for hsCRP, with waist circumference accounting for 44.8%
of the variance of hsCRP at age 16, and BMI accounting
for 33.1% of variance of hsCRP at age 24, 34.4% at age
25, and 31.1% at age 26. The consistent, independent, and
signiﬁcant association of BMI with hsCRP from age 16
to 26 in our current study emphasizes the pediatric and
young adult cardiovascular ramiﬁcations of obesity [1]. In
a recently reported 23.9 year followup study from age 11.3
years of 4857 American Indian children without diabetes,
endogenous death rates among children with the highest
quartileofBMIweremorethandoublethoseamongchildren
in the lowest BMI quartile (incidence-rate ratio, 2.30, 95%
conﬁdence interval 1.46 to 3.62) [1].
Our report is limited by the small number of girls (n =
37) that had hsCRP measurements at age 16 and then again
at ages 25 and 26, thus limiting the information on tracking
from adolescence into young adulthood. However, tracking
data from age 24 to 26 was available in 147 girls and in 225
from age 25 to 26.
In adults, hsCRP levels have been correlated with the
development of CHD in healthy men [12]a n dw o m e n
[11, 13, 14]. In adults, hsCRP levels are associated with the
traditional CHD risk factors, but also confer independent
information about CHD status and future risk [10, 40].
High childhood hsCRP might be viewed as a useful index
of childhood obesity that would aﬀect progression to
future premature death from endogenous causes [1]a n dt o
atherosclerotic disease [18, 41].
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